Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention
Fig 4
Optimizing 2 bNAb combination therapy in comparison to bi-specific therapy with the same bNAbs.
Combination antibody results for AUC (top) and trough (bottom) suggest that trough is slightly more sensitive to ratio (see curvature of outcome surface and change from optimal ratio denoted by open dot). In general, a single bi-specific bNAb will perform worse than combination therapy if it has the best neutralization potential of both parental lineages under a common interaction model but inherits the faster clearance kinetics. However, if synergetic binding occurs, enhancing the bi-specific potency by 10-fold (see Methods), it is similar or outperforms the optimal combination for all outcomes and doses. “All bNAb1” and “All bNAb2” on the x-axis correspond to 100% dosing of the second bNAb product.